ArticleJournal of Korean medical science2021
Antimicrobial Susceptibility Trends and Risk Factors for Antimicrobial Resistance in
Article in Journal of Korean medical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 19 citations in OpenAlex.
- Optimizing Antibiotic Use for Urinary Tract Infections: A Qualitative Assessment of Regular Prescribing Practices.Yonsei medical journal · 2026Article
- Clinical impact of a multidisciplinary remote-based hybrid antibiotic stewardship program in critically ill patients during COVID-19 pandemic in Korea: a prospective pilot implementation study.Antimicrobial resistance and infection control · 2026Article
- Clinical Risk Factors and Outcomes of Carbapenem-Resistant PInfection and drug resistance · 2026Article
- Antimicrobial Resistance Profiles ofPolish journal of microbiology · 2025Article
- Coexistence of Multidrug Resistance and Hypervirulence-Associated Genes in Clinical Carbapenem-ResistantJournal of microbiology and biotechnology · 2025Article
- Natural phytochemical-based strategies for antibiofilm applications.Chinese medicine · 2025Review
- In Vitro Activity of Novel β-Lactam/β-Lactamase Inhibitors Against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Alizarin, which reduces ExoS, attenuates inflammation by P. aeruginosa in H292 cells.Journal of microbiology (Seoul, Korea) · 2025Article
- Risk Factors for Development and Mortality of Carbapenem-ResistantInfection and drug resistance · 2025Article
- Exploring the antibacterial potential of arthrocolins against extensively drug-resistantFrontiers in microbiology · 2025Article
- Empiric Anti-Pseudomonal β-Lactam Monotherapy Versus Fluoroquinolone Combination Therapy in Patients With Hospital-Acquired Pneumonia: A Multicenter Cohort Study With Propensity Score Matching.Journal of Korean medical science · 2023Article
- Burden of severe infections due to carbapenem-resistant pathogens in intensive care unit.World journal of clinical cases · 2023Review
- Article
- Carbapenem-resistantFrontiers in public health · 2023Article
- Risk factors and outcomes of inpatients with carbapenem-resistantFrontiers in microbiology · 2023Article
- Incidence, antimicrobial resistance and mortality ofFrontiers in public health · 2023Observational
- Carbapenem ResistantInfection and drug resistance · 2022Article
- A Practice Primer and Update on Anti-Bacterial Resistance.Missouri medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundInfections caused by multidrug-resistant
methodsThe medical records of patients with
resultsDuring the study period, 295 patients with
conclusionThe identification of risk factors for antimicrobial resistance and analysis of antimicrobial susceptibility might be important for concordant empirical antimicrobial therapy in patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.